Publications by Lipinski and others during the 1990s led to a proliferation of metrics for compound �quality� in drug discovery programs.  Over the last 15 years, these metrics have become part of medicinal chemistry dogma in many organizations, and molecules that violate these �rules� are often frowned upon.  More recently, there appears to be a backlash against many of these metrics.   In a number of recent publications, authors have complained that these metrics may inhibit creativity, and may not be appropriate for the targets currently being pursued by the pharmaceutical industry.  This presentation will provide an overview of the current state of the art in compound metrics for drug discovery, and examine areas where these metrics can provide benefits as well as liabilities.

All metrics are wrong, some might be useful

247th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.